Please ensure Javascript is enabled for purposes of website accessibility

Will Zoetis' Acquisition Spree Pay Off?

By Luis Sanchez CFA - Mar 13, 2021 at 7:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The animal health leader continues to invest in its future.

There is more than one way to grow a business, and animal healthcare company Zoetis (ZTS 2.48%) has shown that making acquisitions can be a viable option. Over the past few years, Zoetis has expanded by buying businesses in tangential areas to its core animal pharmaceutical business. Will this buying spree pay off?

Zoetis' veterinary diagnostics play

Zoetis has made no less than eight acquisitions over the past few years, half of which are related to its push into the veterinary diagnostics space. Animal health diagnostics is one of the fastest-growing parts of the veterinary industry, with a high-single-digit growth rate expected in the coming years. 

Company Acquired Year Purchase Price Description
Abaxis 2018 $2 billion Global leader in point-of-care diagnostics with a portfolio of instruments and testing kits
ZNLabs 2019 $35 million Full-service veterinary reference labs
Phoenix Lab 2019 $150 million Comprehensive services and access to clinics throughout the Northwest
Ethos Diagnostic Science 2020 N/A Reference lab services with locations in Boston, Denver, and San Diego

Data source: Company financial reports and press releases.

Zoetis' $2 billion acquisition of Abaxis in 2018 was the company's most substantial acquisition, and it also marked the company's entrance into the veterinary diagnostics market. Abaxis provides veterinary equipment, testing kits, and other tools used to help veterinarians test for and diagnose diseases. The Abaxis acquisition gave Zoetis a strong base on which to build its diagnostics business.

Zoetis has made additional diagnostics-related acquisitions to continue building this business segment. Notably, Zoetis has acquired three reference laboratories that are used to process the tests run on the Abaxis equipment.

Cat sitting on a scale in a veterinary clinic

Image source: Getty Images.

All of these acquisitions put Zoetis squarely in competition with Idexx Labs (IDXX 2.03%), the leader in the veterinary diagnostics industry. Idexx is currently the undisputed champion within diagnostics, bringing in almost $2.4 billion in diagnostic revenue in 2020 compared to Zoetis' $305 million. Zoetis will have a lot of catching up to do, as Idexx has a strong global presence and a sticky business model centered around being a one-stop shop for veterinarians in diagnostics.

However, there is significant upside to be had if Zoetis can make inroads in diagnostics. The diagnostics business itself is attractive but Zoetis can probably sell more pharmaceuticals to clinics if it has a more holistic relationship with them. This is all to say that it will be interesting to see how Zoetis continues to build its diagnostics business through acquisitions and organic growth.

Zoetis' other acquisitions

Outside of diagnostics, Zoetis has been pursuing bolt-on acquisitions to improve its smaller operating lines. For example, Zoetis' recent acquisition of Performance Livestock Analytics adds a software platform that it can sell to farmers to make farms more efficient.

Company Acquired Year Purchase Price Company Description
Platinum Performance 2019 N/A Provides animal health nutrition drugs
Performance Livestock Analytics 2020 $140 million Helps improve livestock farming by combining automated data collection and analytical software
Fish Vet Group 2020 $20 million Handles environmental analysis for fish producers and offers diagnostic lab services.
Virtual Recall 2020 N/A Helps with veterinary practice management by using automation to reorder medicines and book appointments.

Data source: Company financial reports and press releases.

By the looks of the company's acquisitions, Zoetis is building a diverse array of products above and beyond its legacy in pharmaceuticals that it can leverage to grow into tangential businesses such as diagnostics and business management.

The strategy will be successful if Zoetis can drive meaningful growth from these new business lines. It may be too early to judge, but so far Zoetis still primarily makes its money from selling pet and livestock pharmaceuticals. Diagnostics and business management tools are interesting products, but they are not moving the needle for the company yet.

Long-term growth in animal healthcare

Zoetis is one of the largest animal healthcare companies, which is primarily attributable to its massive success in pharmaceutical products. However, the company has also used acquisitions to break into other areas of animal care.

Growth investors should pay attention to what Zoetis is doing. The animal healthcare industry has been growing at an attractive clip due to positive trends in pet ownership, spending per pet, and the increasing demand for livestock animals to feed the world.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zoetis Inc. Stock Quote
Zoetis Inc.
$162.56 (2.48%) $3.93
IDEXX Laboratories, Inc. Stock Quote
IDEXX Laboratories, Inc.
$372.23 (2.03%) $7.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.